Related Experiment Video
Updated: May 26, 2026
14:34
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Identifying HER2 inhibitors from natural products database.
Shun-Chieh Yang1, Su-Sen Chang, Calvin Yu-Chian Chen
1Laboratory of Computational and Systems Biology, China Medical University, Taichung, Taiwan.
Plos One
|December 17, 2011
Summary
Natural compounds show promise as HER2 inhibitors for cancer therapy. These compounds exhibit potent activity and stable binding to HER2, suggesting they could effectively block cancer cell formation and spread.
Area of Science:
- Oncology
- Computational Chemistry
- Drug Discovery
Background:
- Abnormal human epidermal growth factor receptor 2 (HER2) expression is a key factor in cancer development and progression.
- Inhibiting HER2 is a crucial strategy in cancer therapeutics to restrict tumor formation and metastasis.
Purpose of the Study:
- To evaluate the potential of natural compounds as HER2 inhibitors using computational methods.
- To predict the biological activity and assess the binding stability of natural compounds with HER2.
Main Methods:
- Ligand-based and structure-based studies were performed.
- Multiple linear regression (MLR) and support vector machine (SVM) models predicted biological activities.
- Molecular dynamics (MD) simulations assessed the stability of natural compounds with HER2.
Main Results:
- MLR and SVM models showed strong agreement, predicting significant bioactivity for the natural compounds.
- MD simulations indicated that the natural compounds formed stable conformations with HER2, with enhanced stability compared to Lapatinib.
- Key amino acids (Lys724, Lys736, Thr798, Cys805, Asp808) were identified as critical for binding and stability.
Conclusions:
- The studied natural compounds demonstrate good ligand efficacy and stable binding affinities to HER2.
- These compounds are potent candidates for HER2 inhibitor development, potentially blocking ATP binding site access and downstream signaling.
- Drug design strategies focusing on specific functional groups can further enhance protein-ligand stability for improved HER2 inhibition.
